VERVE-102 Gene Editing Shows Sustained Cholesterol Reduction in Phase 1 Clinical Trial
According to results published on May 25, 2026, in NEJM, a single infusion of VERVE-102 (PCSK9 base editing) led to a dose-dependent reduction in LDL cholesterol of up to 62% in patients with familial hypercholesterolemia. The effect persisted for more than a year in 15 participants, and the safety profile was deemed acceptable.
This is one of those rare cases where headlines in Bloomberg and NEJM are not just noise, but a harbinger of a tectonic shift. The VERVE-102 data released on May 25 in NEJM is a time bomb under cardiology in 2030.
But Wall Street analysts, as usual, are missing the main point. They are looking at PCSK9, but they should be looking at the delivery system.
I am writing this analysis for those who want to understand where the billion-dollar opportunity will be in five years.
[The Gist]: What is Really Happening
The official version: "A single infusion of VERVE-102 reduces 'bad' cholesterol by 62%, with the effect lasting at least a year and a half."
The unofficial version: Eli Lilly just announced the death of the $10+ billion chronic injection market.
We are used to cardiovascular disease therapy being "a daily pill or a shot every two weeks." VERVE-102 breaks this business model. It's "one IV drip and forget about it." The numbers speak for themselves: even at the lowest dose, you get a lifelong protective effect comparable to a natural mutation found in 2% of people.
But the most interesting part is not the cholesterol. The most interesting part is GalNAc-LNP. This lipid nanoparticle is the real value of the deal.
Timeline and Context
Many have forgotten (or never knew) that in July 2025, Lilly paid $1 billion for Verve Therapeutics. At the time, the market thought: "Well, another fake in genetic engineering, bought for $1 billion — no big deal."
Then a competitor hit a snag: Intellia (NTLA-2001) received an FDA clinical hold due to hepatotoxicity in October 2025. Classic CRISPR-Cas9 with double-strand DNA breaks showed its dark side in the liver.
And now, on May 25, 2026, Lilly releases VERVE-102 results. This is base editing. No double-strand breaks. No risk of large chromosomal rearrangements. Haploinsufficiency? Never heard of it.
- 0.3 mg/kg: LDL reduction of 9% (misses the mark, commercially uninteresting).
- 1.0 mg/kg: LDL reduction of 62%, PCSK9 reduction of 88%.
The therapy is tolerated like a mild flu: infusion reactions and transient ALT elevation. That's it. 35 patients, data on 15 of them for 18 months.
Who Wins and Who Loses (Non-Obvious Scenarios)
Loser #1 (Obvious): Amgen ($REPATHA).
The Repatha market in 2024 was $2.2 billion. The overall PCSK9 inhibitor market is around $4 billion. By 2030, this market was supposed to reach $10 billion+. But VERVE-102 makes biweekly injections obsolete. The problem for Amgen is that even if VERVE-102 never reaches the market, investors now know such technology is possible. Amgen's cardio division multiples will be compressed starting tomorrow.
Loser #2 (Non-Obvious): Novo Nordisk.
"What do the Danes with GLP-1 have to do with this?" you might ask. Currently, 80% of Ozempic and Wegovy prescriptions are for cardioprotection. Novo sells hope for risk reduction. If I can go to a clinic, get a Lilly IV drip, and reliably reduce my LDL by 60% for a decade, why would I need weekly shots for the same heart benefit? GLP-1 now has to compete not with diet, but with gene surgery.
Winner (Non-Obvious): Eli Lilly as a Platform.
Lilly paid $1.3 billion (with CVR) for a technology that can edit any gene in the liver.
Look at Verve's pipeline: they have VERVE-201 (targeting ANGPTL3 — triglycerides).
Now use your imagination: delivery of siRNA or a base editor to the liver for treating glycogen storage disease? Hemophilia? Obesity?
Insight for those paying attention: This same LNP (lipid nanoparticle) is already used in oncology by Beam Therapeutics for delivery to the bone marrow. Lilly didn't buy a cholesterol drug. Lilly bought a courier.
What the Media Isn't Saying
The biggest lie is the "1.5 years" in the data.
NEJM says "follow-up up to 18 months." Lilly's press release says the same.
But the devil is in the details: we still don't know how long this works in humans. We have no data at 3 or 5 years. Adeno-associated viruses (AAV) for gene therapy can "silence" over time, and the effect may wane.
However, there is a key difference: base editing changes DNA permanently in the cell we modified. Hepatocytes live long, but the liver regenerates. If cholesterol levels creep up after 4 years due to cell division (dilution of edited alleles), we would need to inject again. A second dose? What about cross-reactive antibodies to the editor? Medicine does not yet know the answer to this question for such healthy patients.
Forecast: Next 30 Days and 90 Days
Next 30 days:
Stocks of second-tier companies (Beam, Scribe) will rise on the hype wave. Investors will start buying everything related to base editing. Don't fall for it. Only VERVE has human cardio data that hasn't been placed under Clinical Hold.
Next 90 days:
Lilly will announce the Phase 2 design. And that's where the real drama begins.
According to the deal terms, Verve's founders will receive an additional $3 per share (about $300 million) if the first patient is dosed in Phase 3 for ASCVD.
This means the current Phase 1b data is good enough for Lilly's management to accelerate Phase 2 and launch Phase 3 as early as 2027 (instead of 2028).
My opinion: VERVE-102 will become the first approved genomic editing for a common disease. This will happen in 2029-2030.
But Lilly's biggest bet is not in cardiology. $1 billion for access to liver editing technology is cheap. If they cure even one rare liver disease using this platform, the price tag will increase tenfold.
Keep an eye on ALXN (Alexion) and other players in this space — they should be scared. They don't have a "liver torpedo" like Lilly does.
— Editorial Team
